Skip to content

Cortical Vein Thrombosis

Summary

fleuron

  • Rare form of cerebral venous thrombosis affecting superficial cortical veins
  • Presents with focal neurological deficits, seizures, and headache
  • Diagnosis confirmed by neuroimaging, with MRI and MRV being gold standard

Pathophysiology

  • Thrombosis of cortical veins leads to:
    • Localised venous congestion and oedema
    • Potential haemorrhagic infarction
    • Disruption of blood-brain barrier
  • Underlying mechanisms:
    • Hypercoagulable states
    • Endothelial injury
    • Venous stasis

Demographics

  • Incidence: 1.32 per 100,000 person-years
  • More common in:
    • Women (3:1 female to male ratio)
    • Young adults (median age 37 years)
  • Risk factors:
    • Pregnancy and puerperium
    • Oral contraceptive use
    • Thrombophilia
    • Malignancy
    • Dehydration

Diagnosis

  • Clinical presentation:
    • Focal neurological deficits (40-60%)
    • Seizures (30-40%)
    • Headache (70-90%)
  • Laboratory tests:
    • D-dimer (elevated in 94% of cases)
    • Thrombophilia screening
  • Neuroimaging:
    • CT/CTA: may show hyperdense cortical veins, 'cord sign'
    • MRI/MRV: gold standard for diagnosis

Imaging

  • Non-contrast CT:
    • Hyperdense cortical veins ('cord sign')
    • Parenchymal oedema or haemorrhage
  • CT venography:
    • Filling defects in cortical veins
  • MRI:
    • T1: hyperintense thrombus in cortical veins
    • T2*/SWI: 'blooming' artefact in thrombosed veins
    • DWI: may show restricted diffusion in affected parenchyma
  • MR venography:
    • Absence of flow in affected cortical veins
    • 'Tram-track' sign on contrast-enhanced images

panels-1

  • A 60-year-old patient presented with a headache following a gastrointestinal illness.
  • MRI showed a large haematoma centred on Heschl's gyrus.
  • Serpigionous T1-hyperintensity over the temporal lobe represented acute thrombus in the vein of Labbe.

Treatment

  • Anticoagulation:
    • Low molecular weight heparin or unfractionated heparin
    • Transition to oral anticoagulants (warfarin or direct oral anticoagulants)
    • Duration: typically 3-12 months
  • Supportive care:
    • Seizure prophylaxis
    • Management of intracranial pressure
  • Endovascular intervention:
    • Consider in severe cases refractory to medical management
    • Mechanical thrombectomy or local thrombolysis
  • Long-term follow-up:
    • Monitor for recurrence and complications
    • Address underlying risk factors

Differential diagnosis

Differential Diagnosis Differentiating Feature
Subarachnoid haemorrhage Absence of "empty delta" sign on CT; different distribution of blood on imaging
Cerebral abscess Ring-enhancing lesion with restricted central DWI; smooth thin capsule; no venous occlusion
Arterial ischaemic stroke Arterial territory distribution; absence of haemorrhagic components in early stages
Tumour (e.g., glioma) Mass effect; irregular enhancement pattern; absence of venous thrombosis on imaging
Reversible cerebral vasoconstriction syndrome Thunderclap headache; "string of beads" appearance on angiography
Cerebral vasculitis Multifocal infarcts; vessel wall enhancement on high-resolution MRI
Posterior reversible encephalopathy syndrome Predominant posterior circulation involvement; reversible oedema
Encephalitis Diffuse brain involvement outside of venous territory